Procyon Corporation
Procyon Corporation, together with its subsidiaries, manufactures and markets wound and skin care products primarily in the United States. It provides AMERIGEL, an advanced skin and wound care products, including hydrogel wound dressing, post op surgical kits, saline wound washes, and care and barrier lotions; HELIX3 Bioactive Collagen products, such as collagen powder, gel, and matrix; and calci… Read more
Procyon Corporation - Asset Resilience Ratio
Procyon Corporation (PCYN) has an Asset Resilience Ratio of 18.18% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Procyon Corporation's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Procyon Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $582.68K | 18.18% |
| Total Liquid Assets | $582.68K | 18.18% |
Asset Resilience Insights
- Good Liquidity Position: Procyon Corporation maintains a healthy 18.18% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Procyon Corporation Industry Peers by Asset Resilience Ratio
Compare Procyon Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Procyon Corporation (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Procyon Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 9.65% | $332.77K | $3.45 Million | -8.54pp |
| 2024-06-30 | 18.18% | $582.68K | $3.20 Million | +2.40pp |
| 2023-06-30 | 15.78% | $562.47K | $3.56 Million | +8.39pp |
| 2022-06-30 | 7.39% | $281.11K | $3.80 Million | +0.78pp |
| 2021-06-30 | 6.61% | $280.44K | $4.24 Million | +1.11pp |
| 2020-06-30 | 5.50% | $155.13K | $2.82 Million | -0.82pp |
| 2019-06-30 | 6.32% | $153.95K | $2.43 Million | -0.18pp |
| 2018-06-30 | 6.51% | $153.46K | $2.36 Million | +2.77pp |
| 2017-06-30 | 3.74% | $102.14K | $2.73 Million | -1.13pp |
| 2016-06-30 | 4.87% | $152.00K | $3.12 Million | -1.39pp |
| 2015-06-30 | 6.27% | $157.67K | $2.52 Million | +0.29pp |
| 2014-06-30 | 5.98% | $157.15K | $2.63 Million | +0.09pp |
| 2013-06-30 | 5.89% | $156.42K | $2.66 Million | -3.06pp |
| 2008-06-30 | 8.95% | $239.70K | $2.68 Million | -- |